Position in LLY
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$64,745,235
+$13,477,257 QoQ
Shares Held
53,980
-3.2% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
1.42%
of 13F equity value
Holder Rank
#479
of 4,605 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 56%
Shared 0%
None 44%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Sterling Capital Management LLC holds $175,509,703 across 14 Drug Manufacturers - General names. LLY ranks #1 (36.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
53,980 | $64,745,235 | |
| 2 | ABBV |
AbbVie Inc.
|
178,425 | $44,898,866 | |
| 3 | AMGN |
Amgen Inc
|
58,377 | $21,139,478 | |
| 4 | MRK |
Merck & Co., Inc.
|
108,307 | $13,917,449 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
220,345 | $12,696,278 | |
| 6 | JNJ |
Johnson & Johnson
|
30,107 | $7,646,273 | |
| 7 | AZN |
Astrazeneca PLC
|
14,562 | $2,761,245 | |
| 8 | NVO |
Novo Nordisk A S
|
49,472 | $2,371,687 |
All Filings in LLY
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $64,745,235 | 53,980 | Shares | Defined | 2026-07-28 | |
| 2026-03-31 | $51,267,978 | 55,740 | Shares | Defined | 2026-04-22 | |
| 2025-12-31 | $65,928,399 | 61,347 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $35,363,524 | 46,348 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $40,339,118 | 51,748 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $36,118,696 | 43,732 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $35,718,124 | 46,267 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $39,994,875 | 45,144 | Shares | Sole | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||